메뉴 건너뛰기




Volumn 171, Issue 12, 2011, Pages 1100-1107

Study of neurontin: Titrate to effect, profile of safety (STEPS) trial - A narrative account of a gabapentin seeding trial

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN;

EID: 79960118526     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.241     Document Type: Article
Times cited : (41)

References (43)
  • 2
    • 49849101435 scopus 로고    scopus 로고
    • The ADVANTAGE seeding trial: A review of internal documents
    • Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med. 2008;149(4):251-258.
    • (2008) Ann Intern Med , vol.149 , Issue.4 , pp. 251-258
    • Hill, K.P.1    Ross, J.S.2    Egilman, D.S.3    Krumholz, H.M.4
  • 4
    • 33747085562 scopus 로고    scopus 로고
    • Narrative review: The promotion of gabapentin: An analysis of internal industry documents
    • Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145(4):284-293. (Pubitemid 46768613)
    • (2006) Annals of Internal Medicine , vol.145 , Issue.4 , pp. 284-293
    • Steinman, M.A.1    Bero, L.A.2    Chren, M.-M.3    Landefeld, C.S.4
  • 7
    • 33744997470 scopus 로고    scopus 로고
    • Every document and picture tells a story: Using internal corporate document reviews, semiotics, and content analysis to assess tobacco advertising
    • DOI 10.1136/tc.2005.013854
    • Anderson SJ, Dewhirst T, Ling PM. Every document and picture tells a story: using internal corporate document reviews, semiotics, and content analysis to assess tobacco advertising. Tob Control. 2006;15(3):254-261. (Pubitemid 43864882)
    • (2006) Tobacco Control , vol.15 , Issue.3 , pp. 254-261
    • Anderson, S.J.1    Dewhirst, T.2    Ling, P.M.3
  • 8
    • 0003012924 scopus 로고    scopus 로고
    • How cigarette design can affect youth initiation into smoking: Camel cigarettes 1983-93
    • Wayne GF, Connolly GN. How cigarette design can affect youth initiation into smoking: Camel cigarettes 1983-93. Tob Control. 2002;11(suppl 1):I32-I39.
    • (2002) Tob Control , vol.11 , Issue.SUPPL. 1
    • Wayne, G.F.1    Connolly, G.N.2
  • 9
    • 42249098105 scopus 로고    scopus 로고
    • Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation
    • DOI 10.1001/jama.299.15.1800
    • Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299(15):1800-1812. (Pubitemid 351549971)
    • (2008) JAMA - Journal of the American Medical Association , vol.299 , Issue.15 , pp. 1800-1812
    • Ross, J.S.1    Hill, K.P.2    Egilman, D.S.3    Krumholz, H.M.4
  • 10
    • 79960111418 scopus 로고
    • Fax from Andrea Rose to Dr. XXXXX: Informed consent form and clinical study agreement for Neurontin STEPS study
    • March 30, Bates Nos. WLC/CBU 137698-137710 Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Fax from Andrea Rose to Dr. XXXXX: Informed consent form and clinical study agreement for Neurontin STEPS study. March 30, 1995. Bates Nos. WLC/CBU 137698-137710. http://www.egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU -137698.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 14
    • 79960146469 scopus 로고
    • Letter from Peter Kaplan to Andrea Rose re: STEPS IRB approval
    • May 1, Bates Nos. Pfizer/TMF/CRF 0046561-45568. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Letter from Peter Kaplan to Andrea Rose re: STEPS IRB approval. May 1, 1995. Bates Nos. Pfizer/TMF/CRF 0046561-45568. http://www.egilman.com/neurontindocs/ STEPS %20Docs/PFIZER-TMF-CRF-046561.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 15
    • 79960119863 scopus 로고
    • Parke- Davis record of FDA contact by Irwin Martin
    • November 30, Bates Nos. WLC/CBU 119162-119168. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis record of FDA contact by Irwin Martin. November 30, 1994. Bates Nos. WLC/CBU 119162-119168. http://www.egilman.com/neurontindocs/STEPS %20Docs/WLC-CBU-119162.pdf. Accessed December 26, 2010.
    • (1994) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 16
    • 79960144819 scopus 로고    scopus 로고
    • Parke- Davis memo from Patrick Reichenberger to John McCarthy re: Neurontin activities
    • April 11, Bates Nos. WLC/CBU 035854-035855. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Patrick Reichenberger to John McCarthy re: Neurontin activities. April 11, 1997. Bates Nos. WLC/CBU 035854-035855. http://www.egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU-035854.pdf. Accessed December 26, 2010.
    • (1997) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 17
    • 79960121809 scopus 로고    scopus 로고
    • Letter from Barbara Rainville to Andrea Rose-Legat re: Data clean-up process
    • April 17, Bates Nos. Pfizer/TMF/CRF 0046087-0046093. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Letter from Barbara Rainville to Andrea Rose-Legat re: data clean-up process. April 17, 1996. Bates Nos. Pfizer/TMF/CRF 0046087-0046093. http://www.egilman. com /neurontindocs/STEPS%20Docs/PFIZER-TMF-CRF-046087.pdf. Accessed December 26, 2010.
    • (1996) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 18
    • 79960132629 scopus 로고    scopus 로고
    • Letter from Jo-Anne Paul to Paula Podolnick re: STEPS: seizure frequency assessment visits
    • January 20, Bates Nos. Pfizer/TMF/CRF 047477-047478. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Letter from Jo-Anne Paul to Paula Podolnick re: STEPS: seizure frequency assessment visits. January 20, 1997. Bates Nos. Pfizer/TMF/CRF 047477-047478. http://www.egilman.com/neurontindocs/STEPS%20Docs/PFIZER-TMF-CRF-047477.pdf. Accessed December 26, 2010.
    • (1997) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 19
    • 79960123770 scopus 로고    scopus 로고
    • Parke- Davis Memo from Laura Johnson to area business managers re: Northeast Anticonvulsant Advisory Board Meeting
    • January 4, Bates Nos. WLC/CBU 156787-156788. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis Memo from Laura Johnson to area business managers re: Northeast Anticonvulsant Advisory Board Meeting. January 4, 1996. Bates Nos. WLC/CBU 156787-156788. http://www.egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU-156787. pdf. Accessed December 26, 2010.
    • (1996) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 20
    • 79960128286 scopus 로고
    • Parke- Davis marketing report re 1995 Neurontin situation analysis
    • September 20, Bates Nos. WLC/CBU 094876-094883 Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis marketing report re 1995 Neurontin situation analysis. September 20, 1995. Bates Nos. WLC/CBU 094876-094883. http://www.egilman.com/ neurontindocs/STEPS%20Docs/WLC-CBU-094876.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 21
    • 79960136046 scopus 로고
    • Parke- Davis memo re: Revised North Central CBU Neurontin "Plus" Plan
    • April 19, Bates Nos. WLC/CBU 136177-136190. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo re: revised North Central CBU Neurontin "Plus" Plan. April 19, 1995. Bates Nos. WLC/CBU 136177-136190. http://www.egilman.com/ neurontindocs /STEPS%20Docs/WLC-CBU-136177.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 22
    • 79960115426 scopus 로고
    • Parke-Davis memo from Tom Gorda to the NECBU re: Neurontin "Plus" Plans
    • June 2, Bates Nos. WLC/CBU 153605-153606. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke-Davis memo from Tom Gorda to the NECBU re: Neurontin "Plus" Plans. June 2, 1995. Bates Nos. WLC/CBU 153605-153606. http://www.egilman.com/ neurontindocs /STEPS%20Docs/WLC-CBU-153605.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 23
    • 79960110963 scopus 로고
    • Parke- Davis Memo re: Neurontin STEPS videoconference
    • December 30, Bates Number WLC/CBU 146788 Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis Memo re: Neurontin STEPS videoconference. December 30, 1994. Bates Number WLC/CBU 146788. http://www.egilman.com/neurontindocs/STEPS %20Docs/WLC-CBU-146778.pdf. Accessed December 26, 2010.
    • (1994) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 24
    • 79960117864 scopus 로고
    • Parke- Davis Powerpoint re: CNS Marketing Task Force Briefing
    • March 30, Bates Nos. WLC/CBU 084368-84401. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis Powerpoint re: CNS Marketing Task Force Briefing. March 30, 1995. Bates Nos. WLC/CBU 084368-84401. http://www.egilman.com/neurontindocs/STEPS %20Docs/WLC-CBU-084368.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 25
    • 79960146967 scopus 로고
    • Parke- Davis meeting minutes on Neurontin Development Team Meeting
    • March 16, Bates Nos. WLC/CBU 170739-170744. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis meeting minutes on Neurontin Development Team Meeting. March 16, 1995. Bates Nos. WLC/CBU 170739-170744. http://www.egilman.com/neurontindocs /STEPS%20Docs/WLC-CBU-170739.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 26
    • 79960143502 scopus 로고
    • Parke- Davis collected materials on Introductory Investigators briefing
    • March 4, Bates Nos. WLC/CBU 036290-036376 Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis collected materials on Introductory Investigators briefing. March 4, 1995. Bates Nos. WLC/CBU 036290-036376. http://www.egilman.com/neurontindocs /STEPS%20Docs/WLC-CBU-036290.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 27
    • 79960145207 scopus 로고
    • Parke- Davis Memo from David Davis to Rick Bancharsky re: STEPS hospital sites
    • January 26, Bates Nos. WLC/CBU 153844-153846 Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis Memo from David Davis to Rick Bancharsky re: STEPS hospital sites. January 26, 1995. Bates Nos. WLC/CBU 153844-153846. http://www.egilman.com /neurontindocs/STEPS%20Docs/WLC-CBU-153844.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 28
    • 79960142047 scopus 로고
    • Parke- Davis memo from Andrea Rose to Parke-Davis distribution list re: Neurontin STEPS study enrollment
    • June 28, Bates Nos. WLC/CBU 153523-153524 Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Andrea Rose to Parke-Davis distribution list re: Neurontin STEPS study enrollment. June 28, 1995. Bates Nos. WLC/CBU 153523-153524. http: //www.egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU- 153523.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 29
    • 79960149616 scopus 로고
    • Parke- Davis memo from Rich Weiss to Mike Hoffman et al re: Neurontin CONTROL study
    • December 5, Bates No. WLC/Franklin 00000039903 Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Rich Weiss to Mike Hoffman et al re: Neurontin CONTROL study. December 5, 1994. Bates No. WLC/Franklin 00000039903. http://www.egilman .com/neurontindocs/STEPS%20Docs/WLC-FRANKLIN-0000039903.pdf. Accessed December 26, 2010.
    • (1994) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 30
    • 79960143921 scopus 로고    scopus 로고
    • Parke- Davis memo from Epilepsy Marketing Team to distribution list re: Situation analysis for Neurontin
    • June 12, Bates Nos. WLC/CBU 090238-090256. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Epilepsy Marketing Team to distribution list re: situation analysis for Neurontin. June 12, 1996. Bates Nos. WLC/CBU 090238-090256. http: //www.egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU- 090238.pdf. Accessed December 26, 2010.
    • (1996) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 31
    • 79960129590 scopus 로고
    • Parke- Davis memo from Jan Rizzo to Lara Ulrich et al re: Selected physician titration analysis
    • July 26, Bates Nos. WLC/CBU 089640-089643. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Jan Rizzo to Lara Ulrich et al re: selected physician titration analysis. July 26, 1995. Bates Nos. WLC/CBU 089640-089643. http://www .egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU-089640.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 32
    • 79960129590 scopus 로고
    • Parke- Davis memo from Jan Rizzo to Lara Ulrich et al re: Selected physician titration analysis
    • November 9, Bates Nos. WLC/CBU 089593-089595 Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Jan Rizzo to Lara Ulrich et al re: selected physician titration analysis. November 9, 1995. Bates Nos. WLC/CBU 089593-089595. http://www .egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU-089593.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 33
    • 79960123146 scopus 로고
    • Parke- Davis memo from Lawton Griffin to Edda Guerrero re: AED monthly reports
    • October 23, Bates Nos. WLC/Franklin 000033263-0000033271. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Lawton Griffin to Edda Guerrero re: AED monthly reports. October 23, 1995. Bates Nos. WLC/Franklin 000033263-0000033271. http://www .egilman.com/neurontindocs/STEPS%20Docs/WLC-FRANKLIN-0000033263 .pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 34
    • 79960123146 scopus 로고
    • Parke-Davis memo from Lawton Griffin to Edda Guerrero re: AED monthly reports
    • December 7, Bates Nos.WLC/CBU146230-146239. Accessed December 26, 2010
    • Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke-Davis memo from Lawton Griffin to Edda Guerrero re: AED monthly reports. December 7, 1995. Bates Nos.WLC/CBU146230-146239. http://www.egilman.com/ neurontindocs /STEPS%20Docs/WLC-CBU-146230.pdf. Accessed December 26, 2010.
    • (1995) Neurontin Marketing, Sales Practices, and Product Liability Litigation
  • 35
    • 33745235139 scopus 로고    scopus 로고
    • How conducting a clinical trial affects physicians' guideline adherence and drug preferences
    • Andersen M, Kragstrup J, Søndergaard J. How conducting a clinical trial affects physicians' guideline adherence and drug preferences. JAMA. 2006;295(23): 2759-2764.
    • (2006) JAMA , vol.295 , Issue.23 , pp. 2759-2764
    • Andersen, M.1    Kragstrup, J.2    Søndergaard, J.3
  • 36
    • 0004177252 scopus 로고    scopus 로고
    • Web site. Accessed December 26, 2010
    • Declaration of Helsinki. http://www.wma.net/en/30publications/10policies/ b3 /index.html. World Medical Association Web site. Accessed December 26, 2010.
    • Declaration of Helsinki
  • 37
    • 41149152920 scopus 로고    scopus 로고
    • Protection of human subjects
    • Accessed December 26, 2010
    • Protection of human subjects. Code of Federal Regulations. http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm. Accessed December 26, 2010.
    • Code of Federal Regulations


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.